| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0dad16690150ae880f1f89020a79ca4b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198 |
| filingDate |
2017-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49d12160c5d8adf0b4cbee5e7a74453b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1e8a426d7424ad687a8fbc8238bd148
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_032d3270fa743dcf14952383d59ab161
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8a113dcab840d51039011485902ffd4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_251a638618239f966ccc09a06af49680
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d7931e085556d4f9b1fb3d7e8788c02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf003aaecc169d94f32bffa10222c2ce |
| publicationDate |
2017-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017119679-A1 |
| titleOfInvention |
Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms |
| abstract |
The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about 10 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020230089-A1 |
| priorityDate |
2010-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |